Words of Wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
| Autor: | Rampersaud EN Jr; Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Belldegrun AS |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European urology [Eur Urol] 2011 Feb; Vol. 59 (2), pp. 301-2. |
| DOI: | 10.1016/j.eururo.2010.11.009 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect